HROW
Get informed when a big investor buys or sells
+ FollowOvervalued by 64.9% based on the discounted cash flow analysis.
| Market cap | $1.39 Billion |
|---|---|
| Enterprise Value | $1.61 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $-0.14 |
| Beta | 0.25 |
| Outstanding Shares | 37,350,401 |
| P/E Ratio | -37.55 |
|---|---|
| PEG | 8.42 |
| Price to Sales | 5.51 |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | 5.83 |
| Enterprise Value to EBIT | -69.31 |
| Enterprise Value to Net Income | -44 |
| Total Debt to Enterprise | 0.19 |
| Debt to Equity | 19.79 |
No data
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.3717▼ 13.38% |
|---|---|
| Total Calls | 1,334,800▲ 23.51% |
| Total Puts | 496,100▼ 9.19% |
Holdings and activity of institutional investors.
| Ownership % | 62.72%▲ 4.48% |
|---|---|
| Total Invested | $960.84M▲ 27.22% |
| Investors Holding | 233▲ 7.00% |
No data
Harrow Health, Inc. owns a portfolio of ophthalmic pharmaceutical businesses, including ImprimisRx, the nation's leading ophthalmology outsourcing facility and pharmaceutical compounding business. The company holds large equity positions...